دورية أكاديمية
Immunogenicity and Safety of Anti-SARS-CoV-2 mRNA Vaccines in a Cohort of Patients with Hereditary Angioedema
| العنوان: | Immunogenicity and Safety of Anti-SARS-CoV-2 mRNA Vaccines in a Cohort of Patients with Hereditary Angioedema |
|---|---|
| المؤلفون: | Ilaria Mormile, Maria Celeste Gigliotti, Angelica Petraroli, Antonio Cocchiaro, Alessandro Furno, Francescopaolo Granata, Francesca Wanda Rossi, Giuseppe Portella, Amato de Paulis |
| المساهمون: | Mormile, Ilaria, Gigliotti, MARIA CELESTE, Petraroli, Angelica, Cocchiaro, Antonio, Furno, Alessandro, Granata, Francescopaolo, Rossi, FRANCESCA WANDA, Portella, Giuseppe, DE PAULIS, Amato |
| سنة النشر: | 2023 |
| المجموعة: | IRIS Università degli Studi di Napoli Federico II |
| مصطلحات موضوعية: | COVID-19, angioedema, anti-SARS-CoV-2 mRNA vaccine, hereditary angioedema, hereditary angioedema due to C1-esterase inhibitor deficiency |
| الوصف: | Many factors may trigger hereditary angioedema (HAE) attacks. This study aims to gain insights into the benefits and potential risks of COVID-19 vaccination in HAE patients, focusing particularly on the possibility of triggering attacks. We enrolled 31 patients with HAE undergoing two doses of the SARS-CoV-2 mRNA Comirnaty-BioNTech/Pfizer vaccine. To evaluate the possible influence of the vaccine on disease control and attack frequency, we administered the angioedema control test (AECT) 4-week version before (T0), 21 days after the first dose (T1), and between 21 and 28 days after the second dose (T2). Despite 5 patients (16.1%) experiencing attacks within 72 h of the first dose administration, no significant variation in attack frequency was observed before and after vaccination [F(2,60) = 0.123; p = 0.799]. In addition, patients reported higher AECT scores at T1 and T2 compared to T0 [F(2,44) = 6.541; p < 0.05; post hoc p < 0.05)], indicating that the disease was rather more controlled after vaccinations than in the previous period. All patients showed a positive serological response to the vaccine without significant differences from healthy controls (U = 162; p = 0.062). These observations suggest that the vaccine administration is safe and effective in HAE patients. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | volume:11; issue:2; firstpage:215; lastpage:225; numberofpages:11; journal:VACCINES; https://hdl.handle.net/11588/913535Test; https://doi.org/10.3390/vaccines11020215Test |
| DOI: | 10.3390/vaccines11020215 |
| الإتاحة: | https://doi.org/10.3390/vaccines11020215Test https://hdl.handle.net/11588/913535Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.5DDEDCA1 |
| قاعدة البيانات: | BASE |
| DOI: | 10.3390/vaccines11020215 |
|---|